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Introduction
　Intraductal papilary-mucinous neoplasms (lPMNs) 
are tumors that are classified as true neoplastic cysts 
of the pancreas. IPMNs are characterized by large 
quantities of mucous production, opening of Vater’s 
papila, pancreatic duct dilation, papilomatous 
proliferation of the pancreatic duct, and poor 
infiltration. Although prognosis is excelent in 
noninvasive cases, the postoperative 5-year survival 
rate of invasive cases is 40%–50%. The male to female 
ratio is 2:1. IPMNs are common among elderly 
individuals (mean age for both genders, approxi-
mately 65 years). The preferred site of IPMNs is the 
pancreatic head, which accounts for up to 70% of 
cases1).
　The concept of an IPMN was first reported by 
Ohhashi et al2), who described it as a ‘mucin-
producing pancreatic tumor.’ Since 1990, this 
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disease concept has been confirmed worldwide by the 
Japanese Classification of Pancreatic Carcinoma3), the 
Armed Forces Institute of Pathology4), the Interna-
tional Histological Typing of Tumors of the Exocrine 
Pancreas by the World Health Organization5), and by 
Kimura et al6)-8). Moreover the International Consen-
sus Guidelines for Management of IPMNs were 
published in 20069). In recent years, the concept of a 
new classification of IPMNs, based on immunohisto-
logical subtypes, which was revised according to the 
WHO classification in 2010, has been adopted11), and 
the international consensus guidelines of 2012 for the 
management of IPMN and MCN of the pancreas have 
been published10).
　Our group, Takasu et al12) previously reported a 
retrospective comparative study of the clinicopa-
thological features, degree of malignancy, morphologi-
cal and immunohistological findings and prognosis of 
IPMNs. That study divided IPMNs into the folowing 
four subtypes: gastric, intestinal, pancreatobiliary, 
and oncocytic. Furthermore, IPMNs were histopathol-
ogicaly classified as adenoma/borderline (IPMN with 
low- or intermediate-grade dysplasia), carcinoma in 
situ (IPMN with high-grade dysplasia), or invasive 
carcinoma derived from IPMN (IPMN with an 
associated invasive carcinoma), in which cancer 
development was described according to staging. 
Moreover, Takeshita et al13) from our group reported 
that an MIB-1 labeling index (Ki67) could be used as 
an indicator of the degree of malignancy. However, 
there has not yet been any study in which the 
association between the MIB-1 labeling index (Ki67) 
and the four morphological and immunohistological 
subtypes was investigated. The present study 
therefore aimed to examine the relationship between 
the MIB-1 labeling index (Ki67) and the four 
morphological and immunohistological IPMN sub-
types described above.
Materials and Methods
Patients
　Between 2000 and 2007, we retrospectively 
evaluated 46 patients who had undergone surgery at 
the Department of Gastroenterological and General 
Surgery, Yamagata University, Faculty of Medicine, 
Japan, were histopathologicaly diagnosed as IPMN, 
and in whom immunohistochemical staining was 
possible. Clinical and folow-up information was 
obtained from patient charts.
Subclassification of IPMNs
　The 46 IPMN patients were graded as adenoma/ 
borderline (adenoma, in this paper), carcinoma in 
situ, or invasive carcinoma derived from IPMN 
according to their histological grade. This grading 
corresponded to the WHO IPMN subtype classifica-
tion11) of IPMN with low-/intermediate-grade dyspla-
sia, IPMN with high-grade dysplasia, and IPMN with 
an associated invasive carcinoma, respectively. 
Adenoma (IPMN with low- or intermediate-grade 
dysplasia) showed papilary growth, consisted of a 
higher proportion of columnar cels than the other 
subtypes, and maintained a proper nuclear arrange-
ment as assessed by hematoxylin and eosin (H-E) 
staining. Carcinoma in situ (IPMN with high-grade 
dysplasia) showed a lack of proper nuclear arrange-
ment, enlargement of the nucleus, a definite nuclear 
pole, and a high level of mitosis. We defined invasive 
carcinoma derived from IPMN (IPMN with an 
associated invasive carcinoma) as cancer cels that 
infiltrated  the  basal  membrane  and  invaded 
interstitial connective tissue.
　The 46 cases of IPMN were subclassified into 4 
types (Gastric, Intestinal, Pancreatobiliary, and 
Oncocytic) as described by Furukawa et al14) on the 
basis of their morphological features and their 
immunohistochemical reactivity (MUC1, MUC2, and 
MUC5AC staining). The samples were first classified 
on the basis of their H-E stained findings, after which 
immunohistochemical analysis was performed to 
confirm the results. When the assessment made on 
the basis of H-E staining was inconsistent with the 
immunohistochemicaldata, the H-E stained slides 
were rechecked. If the H-E data remained inconsis-
tent with the immunohistochemical analysis, the H-E 
based  assessment  was  used  rather  than  the 
immunohistochemical based assessment12).
Immunohistochemical staining
　Immunohistological staining was performed using 
the streptavidin-biotin method. Resected specimens 
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were fixed with formalin and embedded in parafin. 
Thin serial sections were made with a microtome. 
After deparafinization, sliced specimens were washed 
with phosphate-bufered saline. The specimens were 
then heated three times in a microwave at 900 W for a 
total of 30 minutes at 100°C. Endogenous peroxidase 
was blocked with 0.3% H2O2. Non-specific staining 
was blocked by incubating the sections in a solution 
containing  3%  skim  milk.  The  sections  were 
subsequently  incubated  with  primary  antibody 
overnight at 4°C. Next, the sections were incubated 
with  a  second  biotinylated  mouse  monoclonal 
antibody  and  peroxidase-labeled  streptavidin 
(LSAB kit; Dako, Glostrup, Denmark) for 1 hour. 
Peroxidase  activity was  then  detected  using 
3,3’-diaminobenzidine. Finaly, counterstaining was 
performed with hematoxylin. The primary antibodies 
used were specific for MUC1 (clone Ma695; dilution 
1:100) (NovoCastra Laboratories, Newcastle upon 
Tyne, UK), MUC2 (clone Cep58; dilution 1:200) 
(NovoCastra Laboratories), MUC5AC (clone CLH2; 
dilution 1:100) (NovoCastra Laboratories), or the 
Ki67 antigen (clone MIB-1; dilution 1:120) (Dako, 
Glostrup, Denmark).
Evaluation of MUC1, MUC2, and MUC5AC staining
　Two to four slides were immunohistochemicaly 
stained per case. The entire neoplasm on each slide 
was microscopicaly examined under low power (×10) 
and the approximate percentage of positively stained 
neoplastic cels was calculated. The neoplasms were 
graded as folows: (-) less than 5% of neoplastic cels 
positive, (+) 5% to 50% of neoplastic cels positive, 
and (++) more than 50% of neoplastic cels positive. 
For invasive carcinoma derived from IPMN, only the 
noninvasive sites were evaluated: sites of apparent 
invasion were not assessed.
Evaluation of MIB-1 staining
　Two to three slides were immunohistochemicaly 
stained per case. More than 5 fields were selected at 
random  and  microscopicaly  analyzed.  In  one 
particular case, five areas were chosen and analyzed 
at a higher magnification (×200). More than 2000 
tumor cels were countedper case. The MIB-1 labeling 
index was calculated as the percentage (%) of the total 
tumor cels that stained positive. In invasive 
carcinoma derived from IPMN, only the noninvasive 
sites were evaluated: sites of apparent invasion were 
not assessed.
　Al of the pathological and immunohistochemical 
investigations of IPMNs were performed, and the 
results were confirmed, by two physicians.
Statistical analysis
　Results are expressed as means ± SD (range). 
Continuous variables were analyzed using Student’s 
t-test. Survival was calculated from the date of 
resection to the date of disease-specific fatality or to 
the date of censoring at the last folow-up. 
Cumulative overal survival rates were calculated 
using the Kaplan-Meier method. Statistical signifi-
cance was defined as P < 0.05. Al analyses were 
carried out using the StatView version 5.0 Software of 
the SAS Institute, Inc.
Results
　Patient clinicopathological characteristics (n = 46) 
are shown in Table 1. The mean age of the patients 
(32 males and 14 females) was 67 ± 10 years (range, 
47–87). Pancreaticoduodenectomy15) was performed 
in 26 patients, distal pancreatectomy with splenec-
tomy in 9, spleen-preserving distal pancreatectomy16) 
in 10, and total pancreatectomy in one patient. 
Histological grade was: adenoma (n = 27), carcinoma 
in situ (n = 9), and invasive carcinoma derived from 
IPMN (n = 10). Subtypes, based on morphological 
features and immunohistochemical reactivity, were as 
folows: gastric (n = 20), intestinal (n =15), panacrea-
tobiliary (n = 9), and oncocytic (n = 2). The overal 
MIB-1 labeling index for al patients was 8.6% ± 9.2% 
(range, 0.34%–29%). The MIB-1 labeling index (Ki67) 
of patients with the gastric type was 4.0% ± 6.8%, 
which was significantly less than that for patients 
with intestinal or pancreatobiliary types (Figure 1). In 
patients with the gastric type there were significantly 
more adenomas observed (n = 17, 86%) than 
carcinomas in situ (n = 3) or invasive carcinomas 
derived from IPMN (n = 0) (Table 2). Similar 
numbers of each histological gradeof tumor were 
found in the intestinal type. Adenomas and invasive 
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　　　　　　　　　　　Table 1. Clinicopathological characteristics of 46 IPMN patients
PD, pancreaticoduodenectomy; DPS, distal pancreatectomy with splenectomy, SPDP, spleen-preserving distal 
pancreatectomy; TP, total pancreatectomy; Adenoma, IPMN with low- or intermediate-grade dysplasia, adenoma, 
or borderline; Carcinoma in situ, IPMN with high-grade dysplasia or non-invasive carcinoma; Invasive carcinoma 
derived from IPMN, IPMN with an associated invasive carcinoma. 
carcinomas derived from IPMN were the most 
common histological grades found in the pancreatobil-
iary type (both, n = 4). The MIB-1 labeling index 
(Ki67) of patients with adenoma and the gastric type 
of IPMN was less than that for patients with 
adenoma and the intestinal type of IPMN (p = 0.04). 
There was no significant diference between the MIB-
1 labeling index of patients with carcinoma in situ 
and the gastric type of IPMN and that for patients 
with carcinoma in situ and the intestinal type of 
IPMN. The survival curve for al 46 patients with 
IPMN is shown in Figure 2. The mean observation 
period was 68.6 ± 36.9 months (range, 6–153 
months). There were seven disease-specific fatalities, 
al of which were invasive carcinomas derived from 
IPMN, including 1, 4, and 2 patients with intestinal, 
pancreatobiliary, and oncocytic subtypes, respectively. 
The 5-year overal survival rate was 84.3%.
　The relationship between survival and MIB-1 
labeling indices of <10% and ≥10% is shown in 
Figure 3. There were no disease-specific fatalities in 
patients with an MIB-1 labeling index of <10%, 
whereas in those with an index of ≥10%, the 5-year 
survival rate was 61.1% and the prognosis was 
apparently poor.
Figure 1. MIB-1 labeling indices of each immunohisto-
logical subtype of IPMN
　Data are shown as means (thick bars) + standard 
deviations (thin bars).
　The MIB-1 labeling index (Ki67) of patients with the 
gastric type was significantly less than that for patients 
with intestinal or pancreatobiliary types.
46No.
67 ± 10Age (mean ± SD)
Sex
32　Men
14　Women
Tumor location
25　Head
20　Body and/or tail
1　Whole
Macroscopic subtype
35　Branch duct type
4　Main duct type
7　Mixed type
Operative procedure
26　PD
9　DPS
10　SPDP
1　TP
Histological grade
27　Adenoma 
9　Carcinoma in situ 
10　Invasive carcinoma derived from IPMN
69 ± 37Observation period (mean ± SD)
7Disease-specific fatality (n)
84.3%Five-year survival rate (%)
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Table 2. Histological grading and MIB-1 labeling index (Ki67) of IPMNs according to immunohistological subtypes
Adenoma, IPMN with low- or intermediate-grade dysplasia, adenoma, or borderline; Carcinoma in situ, IPMN with 
high-grade dysplasia or non-invasive carcinoma; Invasive carcinoma derived from IPMN, IPMN with an associated 
invasive carcinoma; NS, no significant. MIB-1 labeling indexes are expressed as mean ± standard deviation.
* showing actual values. 
Discussion
　Various gastrointestinal cancers are classified 
according to cel and tissue morphology and a 
correlation with clinicopathological characteristics 
and prognosis is acknowledged. Lauren17) classified 
gastric carcinoma into difuse and intestinal types 
and demonstrated that these types correlated with 
clinical characteristics. Kimura et al18) were the first 
to use the terms intestinal type and pancreatobiliary 
type in carcinoma of the papila of Vater, and they 
reported that cases of the pancreatobiliary type had a 
worse prognosis than those of the intestinal type.
OncocyticPancreatobiliaryIntestinalGastric　
Adenoma
04617　N
-1.17 ± 0.54 (0.75-1.92)3.72 ± 3.65 (0.69-9.95)1.47 ± 1.12 (0.34-4.01)　MIB-1 labeling index(%)
p=0.04
Carcinoma in situ
0153　N
-11.06*15.42 ± 7.68 (4.21-23.21)18.26 ± 9.49 (11.02-29)　MIB-1 labeling index(%)
NS
Invasive carcinoma derived from IPMN
2440　N
16,22*21.50 ± 3.11 (18-25)19.50 ± 6.40 (13-25）-　MIB-1 labeling index(%)
Total
291520　N
16,22*11.30 ± 10.35 (0.75-25)11.83 ± 8.95 (0.69-25)3.99 ± 6.78 (0.34-29)　MIB-1 labeling index(%)
Figure 3. Correlation of survival curves with MIB-1 
labeling indices of < 10% and ≥10%
　There were no disease-specific fatalities in patients 
with an MIB-1 labeling index of <10%, whereas in those 
with an index of ≥10%, the 5-year survival rate was 
61.1% and the prognosis was poor.
Figure 2. Survival curves of al 46 patients with IPMN
　The mean observation period was 68.6 ± 36.9 months, 
and the 5-year survival rate was 84.3%.
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　The folowing two classification systems were 
created for IPMNs: Adsay et al19) divided the condition 
into intestinal, pancreatobiliary, and nul types, 
whereas Yonezawa et al20) created two categories: 
vilous dark cel and papilary clear cel types. In a 
further report by Adsay et al21), these authors 
described the concept of intraductal oncocytic 
papilary neoplasms, in which the papila, comprising 
eosinophilic cels, exhibits a complex branching form. 
In 2005, Furukawa et al14) reported a consensus study 
regarding a new IPMN classification that integrated 
these two schools of thought, in which IPMN was 
classified into the folowing four subtypes: gastric, 
intestinal,  pancreatobiliary,  and  oncocytic.  This 
concept was adopted by WHO as their new 
classification system in 201011). We classified the 46 
patients in our study into four subtypes according to 
the classification system of Furukawa et al14). 
According to this system, the histopathological 
subtype  of  IPMN  should  first  be  based  on 
morphological characteristics and then confirmed by 
immunohistological staining. Our study was based on 
this concept. When findings from H–E staining 
difered from those of immunohistological staining, 
we based the classification on both H–E staining and 
the pathological findings colected from at least two 
physicians. However, only a few such cases were 
found in this study. In our group, the prognosis of 
patients with the gastric or intestinal types was more 
favorable than that for patients with the pancreatobil-
iary type12). Moreover, the prognosis of patients with 
invasive carcinomas derived from IPMN tended to 
be better for the intestinal type than for the 
pancreatobiliary type, which may suggest that the 
former is a slow-growing neoplasm.
　IPMN grading for atypia was histopathologicaly 
classified  into  adenoma  (IPMN  with  low- or 
intermediate-grade dysplasia), carcinoma in situ 
(IPMN with high-grade dysplasia), or invasive 
carcinoma derived from IPMN (IPMN with an 
associated invasive carcinoma), in which cancer 
development is described according to staging. 
Takeshita et al13) demonstrated that the MIB-1 
labeling index, Ki67, was higher for patients with 
carcinoma in situ than for patients with adenoma; 
thus, the MIB-1 labeling index was considered as an 
appropriate indicator of the degree of malignancy. 
These authors also suggested that when IPMN is 
diagnosed as carcinoma in situ, it should be surgicaly 
removed.
　On the basis of these two reports, we examined the 
relationship between the MIB-1 labeling index, Ki67, 
which is an indicator of malignancy, and the four 
diferent  morphological  and  immunohistological 
subtypes of IPMN. We found that the MIB-1 labeling 
index  of  patients  with  the  gastric  type  was 
significantly lower than that of patients with the 
other subtypes (Figure 1). Moreover, of the 46 
patients, those with an MIB-1 labeling index of less 
than 10% showed no decrease in survival time after 
surgery  (Figure 3).  In  summary,  our  findings 
regarding the MIB-1 labeling index demonstrate that 
patients with the gastric type, who have a low MIB-1 
index, exhibited a lower degree of malignancy than 
those with other subtypes, who have a higher MIB-1 
index, and that their prognosis was good.
　Similarly, Furukawa et al22) also demonstrated that 
overal prognosis was better for patients with the 
gastric type of IPMN than for patients with other 
IPMN subtypes. It has been postulated that gastric 
type IPMN often displays low- or intermediate-grade 
dysplasia and that malignant transition occurs less-
frequently in patients with gastric type IPMN10), 11). In 
the present study, although adenoma was frequently 
found in patients with gastric type IPMN, invasive 
carcinoma derived from IPMN was not found in these 
patients. On the other hand, some previous studies 
have shown that patients with invasive carcinoma 
derived from gastric type IPMN, which often takes 
the histological finding of tubular adenocarcinoma, 
have a worse prognosis than patients with invasive 
carcinoma derived from intestinal type IPMN22), 23). In 
2002, Adsay et al26) suggested that MUC2-positive 
IPMN, i.e. the intestinal type, whose carcinogenesis 
folows a pathway similar to the adenoma-carcinoma 
sequence in colorectal cancer, is "indolent" disease, 
whereas MUC1 positive IPMN, i.e. the pancreatobili-
ary type, is "aggressive" disease similar to pancreatic 
adenocarcinoma. In addition, there is increasing 
evidence that gastric type IPMN shows a significantly 
higher incidence of KRAS mutations24), and no 
incidence of GNAS mutation compared with the 
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intestinal type25). It has been suggested that the 
carcinogenesis of not only the pancreatobiliary type 
but also the gastric type of IPMN may be the same as 
that of pancreatic adenocarcinoma24), 25). In the light of 
these studies, it is interesting to note that the MIB-1 
labeling index of patients with the gastric type 
difered from that of the intestinal type in this study.
　In the present study, no invasive carcinoma derived 
from IPMN was detected in patients with the gastric 
type, and the MIB-1 labeling index of this type was 
significantly less than that of the other subtypes. 
These results may be due to a diference in 
histological grade of the neoplasm. However, the 
MIB-1 labeling index of patients with the gastric type 
was only less than that of patients with the intestinal 
type for neoplasms that were graded as adenomas. We 
concluded that malignancy of the gastric type of 
IPMN not higher and may be lower than that of other 
subtypes. Although patients with the gastric type of 
invasive carcinomas derived from IPMN may have 
poor prognoses22), 23), such cases were not found in this 
study of 46 cases. We therefore suggest that such 
cases may be rare and, consequently, more of such 
cases should be accumulated for further study.
　In conclusion, gastric type intraductal papilary 
mucinous neoplasms have a low MIB-1 labeling index, 
which demonstrates that malignancy of this subtype 
is lower than that of other subtypes.
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